Palmitic Acid and Human Microvascular Function

Medical College of Wisconsin

Status and phase: Begins enrollment this month; Phase 2

Conditions: Microvascular Health; Microvascular Dysfunction; Obesity and Overweight; Microvasculature; Cardiovascular Diseases; Cardiovascular Diseases (CVD)

Treatments: Drug: Placebo; Dietary Supplement: Quercetin (dietary supplement)

Study type: Interventional

Funder types: Other

Identifiers

NCT06683534

PRO00053081

Details and patient eligibility

About

The goal of this study is to learn how a supplement Quercetin can affect microvascular function.

Participants will:

• give two blood draws of 5 mL each
• have a camera placed under the tongue to take pictures of blood vessels
• have 2 laser Doppler microdialysis catheters placed on the forearm to monitor blood vessels before and after local drug infusion

Researchers will compare blood vessel function of those who take estrogen supplements to those who do not.

Enrollment: 40 estimated patients

Sex: All

Ages: 18 to 40 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Obesity (BMI>30)
• Aged 18-40 years
• English Speaking

Exclusion criteria

• BMI>60
• Resting SBP ≥180 mmHg or DBP ≥ 110mmHg
• Pregnancy or breastfeeding.
• Prior history of myocardial infarction
• Diagnosis of more than 1 risk factor for coronary artery disease (active smoker, diabetes mellitus- type 1 or 2, congestive heart failure, hyperlipidemia, hypertension)
• Active mouth sores that affect the buccal mucosa.

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

40 participants in 2 patient groups, including a placebo group

Use of oral quercetin to improve human microvascular function

Experimental group

Description:

Quercetin is a non-FDA approved, over-the-counter supplement that has been shown to improve oxidative capacity in blood vessels.

Treatment:

Dietary Supplement: Quercetin (dietary supplement)

Placebo

Placebo Comparator group

Description:

A placebo will be administered for 30 days followed by assessment of the subject's microvascular function.

Treatment:

Drug: Placebo